Prognostic significance and clinicopathological features of hypoxic inducible factor-2alpha expression in hepatocellular carcinoma

References

1. ↵
   1. Forner A,
   2. Llovet JM,
   3. Bruix J

   (2012) Hepatocellular carcinoma. Lancet 379:1245–1255.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Fan ST,
   2. Mau Lo C,
   3. Poon RT,
   4. Yeung C,
   5. Leung Liu C,
   6. Yuen WK,
   7. et al.

   (2011) Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 253:745–758.

   OpenUrlCrossRefPubMed
3. ↵
   1. Zheng SS,
   2. Chen XH,
   3. Yin X,
   4. Zhang BH

   (2013) Prognostic significance of HIF-1a expression in hepatocellular carcinoma: a meta-analysis. PLoS ONE 8:e65753.

   OpenUrlCrossRefPubMed
4. ↵
   1. Wiesener MS,
   2. Jürgensen JS,
   3. Rosenberger C,
   4. Scholze CK,
   5. Hörstrup JH,
   6. Warnecke C,
   7. et al.

   (2003) Widespread hypoxia-inducible expression of HIF-2αlpha in distinct cell populations of different organs. FASEB J 17:271–273.

   OpenUrlCrossRefPubMed
5. ↵
   1. Holmquist-Mengelbier L,
   2. Fredlund E,
   3. Löfstedt T,
   4. Noguera R,
   5. Navarro S,
   6. Nilsson H,
   7. et al.

   (2006) Recruitment of HIF-1alpha and HIF-2αlpha to common target genes is differentially regulated in neuroblastoma: HIF-2αlpha promotes an aggressive phenotype. Cancer Cell 10:413–423.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Stang A

   (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Parmar MK,
   2. Torri V,
   3. Stewart L

   (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Li C,
   2. Lu HJ,
   3. Na FF,
   4. Deng L,
   5. Xue JX,
   6. Wang JW,
   7. et al.

   (2013) Prognostic role of hypoxic inducible factor expression in non-small cell lung cancer: a meta-analysis. Asian Pac J Cancer Prev 14:3607–3612.

   OpenUrl
9. ↵
   1. Sun HX,
   2. Xu Y,
   3. Yang XR,
   4. Wang WM,
   5. Bai H,
   6. Shi RY,
   7. et al.

   (2013) Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway. Hepatology 57:1088–1097.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Wang J,
    2. Yi JL,
    3. Wang CJ,
    4. Wang WY,
    5. Xu RH

    (2009) Expression of HIF-2α in hepatocellular Carcinoma and its clinical significance. Journal of Chinese Physician 11:1707–1708.

    OpenUrl
11. ↵
    1. Bangoura G,
    2. Yang LY,
    3. Huang GW,
    4. Wang W

    (2004) Expression of HIF-2αlpha/EPAS1 in hepatocellular carcinoma. World J Gastroenterol 10:525–530.

    OpenUrlPubMedWeb of Science
12. 1. Yang SL,
    2. Liu LP,
    3. Jiang JX,
    4. Xiong ZF,
    5. He QJ,
    6. Wu C

    (2014) The correlation of expression levels of HIF-1a and HIF-2α in hepatocellular carcinoma with capsular invasion, portal vein tumor thrombi and patients’ clinical outcome. Jpn J Clin Oncol 44:159–167.

    OpenUrlCrossRefPubMed
13. ↵
    1. Bangoura G,
    2. Liu ZS,
    3. Qian Q,
    4. Jiang CQ,
    5. Yang GF,
    6. Jing S

    (2007) Prognostic significance of HIF-2αlpha/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol 13:3176–3182.

    OpenUrlPubMedWeb of Science
14. ↵
    1. Wang X,
    2. Yuan Z,
    3. Li S,
    4. Jun S,
    5. Zhao T,
    6. Song G,
    7. et al.

    (2011) Expression of Hypoxia-Inducible Factor-2a in Hepatocellular Carcinoma and its clinical significance. Chinese Journal of Clinical Oncology 39:560–563.

    OpenUrl
15. ↵
    1. Zhang JB,
    2. Guo K,
    3. Zhu XD,
    4. Kong LQ,
    5. Cai ZT,
    6. Wang WQ,
    7. et al.

    (2012) High expression of hypoxia inducible factor 2α in peritumoral liver tissue is associated with early recurrence and poor survival after curative resection of hepatocellular carcinoma. Fudan University Journal of Medical Science 39:449–453.

    OpenUrl
16. ↵
    1. Aravalli RN,
    2. Cressman EN,
    3. Steer CJ

    (2013) Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol 87:227–247.

    OpenUrlCrossRefPubMed
17. ↵
    1. Tang CM,
    2. Yu J

    (2013) Hypoxia-inducible factor-1 as a therapeutic target in cancer. J Gastroenterol Hepatol 28:401–405.

    OpenUrlCrossRefPubMed
18. ↵
    1. Ghanem I,
    2. Riveiro ME,
    3. Paradis V,
    4. Faivre S,
    5. de Parga PM,
    6. Raymond E

    (2014) Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res 6:340–352.

    OpenUrlPubMed
19. ↵
    1. Du J,
    2. Sun B,
    3. Zhao X,
    4. Gu Q,
    5. Dong X,
    6. Mo J,
    7. et al.

    (2014) Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma. Gynecol Oncol 133:575–583.

    OpenUrlCrossRefPubMed
20. ↵
    1. Hu CJ,
    2. Sataur A,
    3. Wang L,
    4. Chen H,
    5. Simon MC

    (2007) The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2αlpha. Mol Biol Cell 18:4528–4542.

    OpenUrlAbstract/FREE Full Text
21. ↵
    1. Mazumdar J,
    2. Hickey MM,
    3. Pant DK,
    4. Durham AC,
    5. Sweet-Cordero A,
    6. Vachani A,
    7. et al.

    (2010) HIF-2αlpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci USA 107:14182–14187.

    OpenUrlAbstract/FREE Full Text
22. ↵
    1. Rankin EB,
    2. Rha J,
    3. Unger TL,
    4. Wu CH,
    5. Shutt HP,
    6. Johnson RS,
    7. et al.

    (2008) Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 27:5354–5358.

    OpenUrlCrossRefPubMedWeb of Science